Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants With Refractory Chronic Cough

NCT07671924 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT07671924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants With Refractory Chronic Cough
Lead sponsor
Trevi Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 22, 2026
Completion date
September 30, 2027
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic cough